Application of Next Generation Sequencing for Detection of Drug Resistance Mutations in Patients Infected with Chronic Viral Hepatitis B and C Diseases

Ali M^{*1}, Zia Z¹, Aziz K¹, Ghaffar M¹, Bengone-Abogourin J², Elfar M³, Mustafa A⁴, Al Qasser M¹

¹Virology Unit, Department of Laboratory, Mubarak Al Kabeer Hospital, Ministry of Health, Kuwait; ² ABL Diagnostics 42, rue Olivier Métra - Bât E1, 75020 Paris, France; ³Gastroenterology Unit, Mubarak Al Kabeer Hospital, Ministry of Health, Kuwait; ⁴Microbiology Department, Faculty of Medicine, Health Science Centre, Kuwait University, Kuwait

Introduction and Objectives

The hepatitis C virus (HCV) and hepatitis B virus (HBV) are blood-borne pathogens causing an inflammation of the liver that can lead to liver damage, hepatocellular carcinoma and death. Although most currently used treatment regimens for HCV and HBV infections can be initiated without prior knowledge of genotypes, however, success rates are negatively influenced by the high genetic variability represented by the circulating genotypes, and the drug-resistant variants among infected individuals specially those on long-term therapy. Although

Results and Discussion

Genotyping determination performed through homology testing of a consensus sequence generated from all the reads mapped to HCV and HBV genomic regions and compared to an updated set of reference sequences. Genotyping results for HCV and HBV (**Figure 5, A and B**) showed a prevalence of genotype 4a followed by 3a and less 1a in accordance with the previously published results on the predominant HCV genotypes in the Middle East. Similarly, prevalence of genotype D for HBV samples reported earlier to cause most severe liver disease.

Α

epChek[®] - HCV Subtyping

Sanger sequencing is the gold standard method for analysing viral mutations; thus, it is unable to determine the profile of a heterogeneous viral population in a patient. On the other hand, Next Generation Sequencing (NGS), is a highthroughput analysis platform which has been recently introduced into diagnostic virology laboratories. It has shown to be efficient in characterizing viral diversity and detecting minor mutants that constitute as little as 1% of the total viral population. Our objective was to optimize NGS for the detection of HBV and HCV genotypes and drug-resistance mutations especially low abundance variants circulating in Kuwait.

Methods

A total of 40 residual serum samples received for routine viral load testing from chronic hepatitis patients attending Gastroenterology Clinic at Mubarak Al Kabeer Hospital (20 for HBV and 20 for HCV) were used to optimize NGS methodology. NGS was standardized using ABL genotyping and drug-resistance assays that relies on specific-primers approach due to their high-resolution in identifying and classifying mixed and recombinant genotypes. The NGS workflow consisted of a robust methodology of the following: (i) for HCV, RT and nested-PCR amplification was applied for all HCV subtypes (1-6) based on NS3, NS5A and NS5BA genomic

	NS3 (Protease)		NS5A (Phosphoprotein)						
	HCV Genotype/Subtype	Similarity (1)			Similarity (1)				
NGS	4a	89.37		NGS	4a	90.41			
	NS5B (Polymerase)							
	HCV Genotype/Subtype	Similarity (1)		E	igure 5 HCV(A)				
NGS	4a	90.06	Figure 5. HCV (A), HBV (B)						

	Polym	erase
	Subtype	Similarity (1)
NGS	D	98.16

(1) Similarity reflects the percentage of aligned bases that are identical to the closest reference sequence

Assessment of resistance-associated substitutions (RAS) and minority variants harboring RAS makes it possible to predict their selection with specific direct acting antivirals against HCV or HBV. This allows for the creation of a final report for RAS that includes recommendations for re-treatment of patients' refractory to the antiviral treatments. Accordingly, physicians will be provided with a summarized clinical report classifying the genotypes and drug-resistance mutations of interest along with treatment-regimen recommendations, **Figures 6 and 7**.

HCV NS5A mutations								SUBT	YPING [Local similarity testin	g]		COVERED POSITIONS				
Position	Mutation	20.00%	10.00%	5.00%	3.00%	Prevalence %	Q-Score	NS	3 4a (85.98 %)	NS5A 4a (90.22	? %)	NS3	9→163		NS5A	1→182
1	A≁T	1	1	1	1	99.13	29	NS	B 4a (90.4 %)			NS5B	45→346			
2	E≁D	1	1	1	1	97.44	29		. ,							
10	D≁N	1	1	1	1	99.65	28		atermination performed through homology testing of a 20 ar region and compared to an updated set of reference se		all the reads mapped to			considered as not covered.	nce sequence for th	e alignment (using BWA v0.7.15 alignment tool).
13	L≁C H≁T	1	1	1	1	95.68 94.96	30	the particul								
<u> 14</u> 20	H+1 K+Q	1	1	-		4.85	<u> </u>		ANTIRETROVIRAL DRUG	INTERPRETATION		DEE	PCHEK [®] HC	CV (Geno2Phen	0 0.92-12-2	2017)
20	C+W	1	1	1	-	95.1	29									
27	F+L		1	1	1	95.03	30		Generic name	Assessment	e mutations >15.00% Re		Resistance m	lesistance mutations between >3% and <15.00%		
28	V≁L	1	1	1	1	50	30									
20	V≁M	1	1	1	1	48.68	30									
30	L≁R				1	3.19	29	NS5B-NI		S						
31	M≁wt	1	1	1	1	98.83	30	с с с	Sofoobuuir							
34	I≁V		1	1	1	12.17	24	22	Sofosbuvir							
<u>36</u> 39	L≁F W≁C	1	1	1	1	98.14 97.68	28 26	ž								
40	P+Q				1	97.68	26									
40	K≁R			1		65.85	27									
50	D≁E				-	4.32	30		Paritaprevir (ABT-450)	S						
62	D≁E	1	1	1	1	99.11	29	<u>a</u>								
93	Y≁H		1	1	1	17.88	31	NS3-PI	Simeprevir	S						
101	l≁V	1	1	1	1	72.16	27	<u>N</u>								
117	D≁E	1	1	1	1	98.5	29	Z	Voxilaprevir	S						
123	R≁K	1	1	1	1	77.73	28									
126	D≁E V≁I		1			20.16	28		Declatectuir	D	V00LL (17 000)	\				
<u>130</u> 140	V≁I F≁C	1	1			17.92 95.15	<u>30</u> 27	_	Daclatasvir	R	Y93H (17.88%)		L30R (3.19%)		
140	L→F	~	1	1		97.89	29	S S	Elbasvir (MK-8742)	R	Y93H (17.88%)				
158	I≁L	1	1	1	1	98.86	30			R	Y93H (17.88%	,				
164	K≁Q				1	3.77	26	2 A	Ledipasvir (GS-5885)			,				
171	D≁E	1	1	1	· · · · · · · · · · · · · · · · · · ·	47.97	30	NS5A-RCI	Ombitasvir (ABT-267)	R	Y93H (17.88%)				
	Subtype 4a <u>Y11604</u> w as used as the reference sequence for the alignment (using BWA v0.7.15 alignment tool). Mutations of interest based on Sorbo 1.0 (Bold red text) Insufficient number of sequences to guarantee, at the 99% confidence level, that all mutations with the given threshold frequency have been found at that position.								Velpatasvir	R	Y93H (17.88%)				
Insufficie									Susceptible	1		ssibly resistant pensatory mutatio	n	R		Resistant

Figure 6. Resistant mutation Y93H and L30H were detected in (60%) of samples with HCV-4a and HCV-3a Elbasvir (MK-8742), Ledipasvir (GS-5885), Ombitasvir (ABT-267) and Velpatasvir. subtypes.

Figure 7. Detected mutations within NS5A region confer resistance to Daclatasvir,

regions, Figure 1. (ii) for HBV, polymerase region was amplified, Figure 2 in a one-round PCR to identify HBV genotypes and drug-resistance mutations of interest. Sequenced data were analysed using DeepCheck Analysis Software which subject raw data to a filtering process and phylogenetic classification using reference HCV and HBV genomes sequences provided from GenBank.



Results and Discussion

All 40 serum samples (20 HCV and 20 HBV) were amplified as shown on **Figure 3** and **Figure 4**, and sequenced using Ion-Torrent S5 NGS platform (ThermoFisher). Sequencing was achieved with a genome coverage and depth of >90% of the HCV and HBV genomic regions covered by >100 reads/site.



HBV mutation detection revealed that all 18 samples showed susceptibility tendency to Adefovir, Entecavir, Lamivudine, Telbivudine and Tenofovir, while, two samples harboured mutation A181T that confer resistant to Adefovir, Lamivudine and Telbivudine Figure 8 and Figure 9.

HBV reverse transcriptase domain mutations						Patient ID Name					ve ID Illected eported	27/11/2022 05/12/2022	Name Institution Address			
Mutation	20.00%	10.00%	Mutational .00% 5.00% 3.00% Prevalence Q-Score load % (cp/mL)		DOB Geno Viral				Sequencing platform Software version Expert system		Thermofisher - Ion S5 2.0 2.3					
G≁R			1	1	8.49	31	69		ple ID							
L≁I		1	1	1	16.82	31	137		ple type	Serum						
R≁M			1	1	7.82	32	63	Salli	ihie type	oelulli						
Y≁H	1	1	1	1	98.48	29	800	LIDV (I cool cimilarity t	ootingl			COVERED POSITIO	MQ	
T+I			1	1	5.77	30	47	пру	SUBITFING	i [Local similarity t	esungj			COVERED POSITIO	110	
N≁S			1	1	9.09	29	74									
A≁S A≁T				<pre> /</pre>	10.64 48.19	31 31	86 391		RT	D (98.26 %)				RT	1→344	
A+1 V+I					48.19	31	431		ni	D (30.20 %)				ni	1707	
 M≁I		~	V	/	3.43	31	28	Subtyping d	determination performe	d through homology testing of a 20%	% consensus sequence aene	erated from all t	the reads mapped to	Positions with less than 100 reads are	considered as not covered.	
L+F		1	1	/	13.73	24	111	this particula	ar region and compare	d to an updated set of reference se	equences.					ment (using BWA v0.7.15 alignment tool).
G+S				1	3.6	30	29		ANTIRE	TROVIRAL DRUG	INTERPRET/			DEEDCI	HEK® HBV (HBVDB 4	3.0)
₩ → *				1	3.86	29	31		ANTINE	HIG VINAL DIOG	INTERPRET/			DEEPCI		
G≁D				1	3.91	30	32							1.11	B. I.I.	
G≁R				1	3.54	30	29		Ge	eneric name	Assessme	ent	Resistance	e mutations >20.00%	Resistance mutat	ions between >3% and <20.00%
C≁S			1	1	5.55	30	45		A 1 4 1							
D≁N				1	3.33	27	27		Adefovir		R	/	A181T (48.19%	%)		
I≁R			1	1	5.64	31	46		Entecavi	r	S				M204I (3.43%)	
₩ > *					4.73	28	38	RTI	LITECAVI	1						
G≁S K≁Q					3.08 3.71	28 29	25 30	Ē	Lamivudi	ine	R	-	A181T (48.19%	%)	M204I (3.43%)	
V+V				~	5.71	29	30	Z			P		,	,	, ,	
496 w as use	d as the re	eference	sequence	for the alic	Inment (using BWA	v0.7.15 alignme	ent tool).		Telbivudi	ine	R	/	A181T (48.19%	/0)	M204I (3.43%)	
based on HBV						0	,		Tenofovi	r			A181T (48.19%	%)		
	quences to	o guarante	ee, at the	99% confi	lence level, that all	mutations with t	he given	S		Sensitive		I		Intermediate	R	Resistant

Figure 8. HBV NGS drug-resistant mutation panel.

128 131

204 228

Mutations of interest ba

Insufficient nu threshold freq

Figure 9. HBV NGS drug-resistant clinical report.

Conclusions: Due to common misclassifications by commercially available genotyping assays in combination with the limitations of currently used Sanger sequencing; this have raised the





Figure 3. shows the amplification of NS3 (700 bp), NS5A (707 bp), NS5BA (693 bp) HCV genomic regions.

Figure 4. shows the amplification of Pol HBV genomic region, fragment G (1363 bp) and fragment H (760 bp).

flag to investigate alternative diagnostic sequencing methods for the clinical management of

patients infected with chronic viral HBV and HCV diseases. NGS technology can be helpful to

physicians in guiding clinical practice and patient therapy management.

Acknowledgments: Ministry of Health for providing the up-to-date NGS platform for diagnostic laboratories purposes. Dr. Ola and Ms. Reem (Bader Sultan) for their continuous support and professionalism. Virology Laboratory Staff and FOM Microbiology Department for their continuous support.